Vor Ort
Merkzettel Warenkorb
Produktbild: Molecular Pharmacology

Molecular Pharmacology From DNA to Drug Discovery

113,99 €

inkl. gesetzl. MwSt., Versandkostenfrei

Beschreibung

Produktdetails

Einband

Taschenbuch

Erscheinungsdatum

19.12.2012

Verlag

John Wiley & Sons Inc

Seitenzahl

424

Maße (L/B/H)

24,6/18,9/2,5 cm

Gewicht

907 g

Auflage

1. Auflage

Sprache

Englisch

ISBN

978-0-470-68443-6

Beschreibung

Rezension

"Overall, it could be the basis of an excellent course forjunior pharmacologists in basic science research who need a greaterfocus on the mechanisms of drug action rather than an encyclopedicsurvey of clinical drug use." ( Doody's , 26July 2013)

Produktdetails

Einband

Taschenbuch

Erscheinungsdatum

19.12.2012

Verlag

John Wiley & Sons Inc

Seitenzahl

424

Maße (L/B/H)

24,6/18,9/2,5 cm

Gewicht

907 g

Auflage

1. Auflage

Sprache

Englisch

ISBN

978-0-470-68443-6

Herstelleradresse

Libri GmbH
Europaallee 1
36244 Bad Hersfeld
DE

Email: gpsr@libri.de

Kundinnen und Kunden meinen

0 Bewertungen

Informationen zu Bewertungen

Zur Abgabe einer Bewertung ist eine Anmeldung im Konto notwendig. Die Authentizität der Bewertungen wird von uns nicht überprüft. Wir behalten uns vor, Bewertungstexte, die unseren Richtlinien widersprechen, entsprechend zu kürzen oder zu löschen.

Die Bewertungen sind nach Format, Anzahl Sterne und Datum sortiert.

Verfassen Sie die erste Bewertung zu diesem Artikel

Helfen Sie anderen Kund*innen durch Ihre Meinung

Kundinnen und Kunden meinen

0 Bewertungen filtern
Die Leseprobe wird geladen.
  • Produktbild: Molecular Pharmacology

  • Preface ix

    Abbreviations x

    1 Introduction to Drug Targets and Molecular Pharmacology 1

    1.1 Introduction to molecular pharmacology 1

    1.2 Scope of this textbook 2

    1.3 The nature of drug targets 3

    1.4 Future drug targets 7

    1.5 Molecular pharmacology and drug discovery 11

    References 12

    2 Molecular Cloning of Drug Targets 13

    2.1 Introduction to molecular cloning - from DNA to drug discovery 13

    2.2 'Traditional' pharmacology 14

    2.3 The relevance of recombinant DNA technology to pharmacology/drug

    discovery 14

    2.4 The 'cloning' of drug targets 15

    2.5 What information can DNA cloning provide? 20

    2.6 Comparing the pharmacologic profile of the 'cloned' and the 'native'

    drug target 23

    2.7 Reverse pharmacology illustrated on orphan GPCRs 24

    2.8 Summary 27

    References 27

    3 G Protein-coupled Receptors 31

    3.1 Introduction to G protein-coupled receptors 31

    3.2 Heterotrimeric G-proteins 36

    3.3 Signal transduction pathways 40

    3.4 Desensitisation and down-regulation of GPCR signalling 44

    3.5 Constitutive GPCR activity 45

    3.6 Promiscuous G-protein coupling 47

    3.7 Agonist-directed signalling 48

    3.8 Allosteric modulators of GPCR function 49

    3.9 Pharmacological chaperones for GPCRs 50

    3.10 GPCR dimerisation 51

    3.11 GPCR splice variants 63

    3.12 Summary 67

    References 67

    Useful Web sites 70

    4 Ion Channels 71

    4.1 Introduction 71

    4.2 Voltage-gated ion channels 73

    4.3 Other types of voltage-gated ion channels 89

    4.4 Ligand-gated ion channels 109

    4.5 Summary 125

    References 125

    5 Transporter Proteins 129

    5.1 Introduction 129

    5.2 Classification 129

    5.3 Structural analysis of transporters 132

    5.4 Transporter families of pharmacological interest 133

    5.5 Transporters and cellular homeostasis 167

    5.6 Summary 169

    References 169

    6 Cystic Fibrosis: Alternative Approaches to the Treatment of a Genetic Disease 175

    6.1 Introduction 175

    6.2 Cystic fibrosis transmembrane conductance regulator 179

    6.3 Mutations in CFTR 183

    6.4 Why is cystic fibrosis so common? 184

    6.5 Animal models of Cystic fibrosis 186

    6.6 Pharmacotherapy 186

    6.7 Gene therapy 191

    6.8 Conclusion 195

    References 196

    7 Pharmacogenomics 201

    7.1 Types of genetic variation in the human genome 201

    7.2 Thiopurine S-methyltransferase and K+ channel polymorphisms 202

    7.3 Polymorphisms affecting drug metabolism 204

    7.4 Methods for detecting genetic polymorphisms 209

    7.5 Genetic variation in drug transporters 211

    7.6 Genetic variation in G protein coupled receptors 215

    7.7 Summary 225

    References 225

    Useful Web sites 226

    8 Transcription Factors and Gene Expression 227

    8.1 Control of gene expression 227

    8.2 Transcription factors 229

    8.3 CREB 233

    8.4 Nuclear receptors 238

    8.5 Peroxisome proliferator-activated receptors 240

    8.6 Growth factors 247

    8.7 Alternative splicing 247

    8.8 RNA editing 251

    8.9 The importance of non-coding RNAs in gene expression 257

    8.10 Summary 270

    References 271

    9 Cellular Calcium 277

    9.1 Introduction 277

    9.2 Measurement of calcium 278

    9.3 The exocrine pancreas 289

    9.4 Calcium signalling in pancreatic acinar cells 292

    9.5 Nuclear calcium signalling 303

    9.6 Conclusions 310

    References 311

    10 Genetic Engineering of Mice 315

    10.1 Introduction to genetic engineering 315

    10.2 Genomics and the accumulation of sequence data 315

    10.3 The mouse as a model organism 318

    10.4 Techniques for genetic engineering 319

    10.5 Examples of genetically-engineered mice 332

    10.6 Summary 334

    References 334

    11 Signalling Complexes: Protein-protein Interactions and Lipid Rafts 339

    11.1 Introduction to cell signalling complexes 339

    11.2 Introduction to GPCR interacting proteins 340

    11.3 Methods used to identify GPCR interacting proteins 340

    11.4 Functional roles of GPCR interacting proteins 345

    11.5 GPCR signalling complexes 348

    11.6 GPCR and ion channel complexes 355

    11.7 Ion channel signalling complexes 356

    11.8 Development of pharmaceuticals that target GPCR interacting proteins 356

    11.9 Development of pharmaceuticals that target protein-protein interactions 356

    11.10 Lipid rafts 357

    11.11 Receptor-mediated endocytosis 361

    11.12 Summary 364

    References 364

    12 Recombinant Proteins and Immunotherapeutics 367

    12.1 Introduction to immunotherapeutics 367

    12.2 Historical background of immunotherapeutics 368

    12.3 Basis of immunotherapeutics 368

    12.4 Types of immunotherapeutics 369

    12.5 Humanisation of antibody therapy 372

    12.6 Immunotherapeutics in clinical practice 376

    12.7 Advantages and disadvantages of immunotherapy 378

    12.8 The future 379

    12.9 Summary 380

    References 380

    Glossary 381

    Index 403